DeNovaMed is a pharmaceutical company specializing in therapeutic approaches to combat bacterial infections. It develops a Gram negative and Gram positive program focused on oral/iv delivery of antibiotics to allow lower, less toxic doses of colistin. The Gram positive program also aims to develop a topical antibiotic for treating diabetic foot infections.